Fact CheckerSign in

NCT07850050Not yet recruitingPhase 3

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

A Multicentre, Randomised, Double-blind, Placebo-controlled 52-week, Phase IIIb Trial to Evaluate the Efficacy and Safety of Survodutide in Peri- and Post-menopausal Women With Overweight or Obesity (SYNCHRONIZE®-HERA)

Source: ClinicalTrials.gov · Last updated 30 Oct 2026

Brief summary (registry, in English)

This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause. People can join this study if they have a Body Mass Index (BMI) of 30 kg/m² or more, or if their BMI is 27 kg/m² or more and they have one or more weight related health problems. Participants must also have tried to lose weight by dieting at least once in the past without success. People with pre-existing diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps women with overweight or obesity lose weight. Participants are put into 2 groups randomly, which means by chance. Participants have a 1 in 2 chance of receiving survodutide. One group gets survodutide as an injection under the skin. The other group gets a placebo as an injection under the skin. The placebo looks like the study medicine but does not contain any medicine. Participants take the injections once a week. All participants also receive advice on diet and physical activity. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site about 12 times and get a few phone calls from the site staff. At the study visits, doctors regularly check participants' body weight. The results are compared between the 2 groups to see whether the treatment works. The participants fill in questionnaires about their menopause symptoms and how the symptoms affect their daily life. To assess the study endpoints, participants regularly have blood samples taken. The doctors also regularly check participants' health and take note of any unwanted effects.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
600 (estimated)
First submitted
25 Sept 2026
Start date
31 Oct 2026
Primary completion date
26 Jul 2028
Lead sponsor
Boehringer Ingelheim
Diseases
Obesity
NCT number
NCT07850050
EU CT number
2026-527092-29-00

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 600
  • From 31 Oct 2026 to the primary completion date, 26 Jul 2028
  • 16 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Treatment with any medication for the indication of obesity within 90 days before screening
  • Body weight change (self-reported) \>5% within 90 days before screening (Visit 1) Further exclusion criteria apply.

Other illness

  • Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM)

Lab values

  • Glycosylated Haemoglobin A1c (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the central laboratory at screening (Visit 1)

Who the study is looking for

  • Signed and dated written informed consent in accordance with International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Female (sex assigned at birth) with age \>18 years at the time of screening
  • History of at least one self-reported unsuccessful dietary effort to lose body weight
  • Women of Childbearing Potential (WOCBP) must be ready and able to use at least an acceptable effective contraceptive method of birth control Further inclusion criteria apply.

Age in the registry: 45 years to 65 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (16)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Glasgow Royal Infirmary
Coordinator of this site? Confirm its status
GlasgowUnited KingdomUnknown status
Leicester General Hospital
Coordinator of this site? Confirm its status
LeicesterUnited KingdomUnknown status
Flourish Research
Coordinator of this site? Confirm its status
BirminghamUnited StatesUnknown status
Flourish Research
Coordinator of this site? Confirm its status
BowieUnited StatesUnknown status
The Center for Diabetes and Endocrine Care
Coordinator of this site? Confirm its status
Fort LauderdaleUnited StatesUnknown status
Jacksonville Center for Clinical Research
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesUnknown status
Flourish Research
Coordinator of this site? Confirm its status
MandevilleUnited StatesUnknown status
Flourish Research
Coordinator of this site? Confirm its status
Merritt IslandUnited StatesUnknown status
Flourish Research
Coordinator of this site? Confirm its status
MetairieUnited StatesUnknown status
Lucas Research, Inc.
Coordinator of this site? Confirm its status
Morehead CityUnited StatesUnknown status
Flourish Research
Coordinator of this site? Confirm its status
NorthridgeUnited StatesUnknown status
West Orange Endocrinology, PA
Coordinator of this site? Confirm its status
OcoeeUnited StatesUnknown status
McKay-Dee Hospital
Coordinator of this site? Confirm its status
OgdenUnited StatesUnknown status
Diabetes Associates Medical Group
Coordinator of this site? Confirm its status
OrangeUnited StatesUnknown status
Covenant Metabolic Specialist, LLC - Riverview
Coordinator of this site? Confirm its status
RiverviewUnited StatesUnknown status
Flourish Research
Coordinator of this site? Confirm its status
Walnut CreekUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.